![5000100-flag[1].jpg](https://cdn.european-virus-archive.com/sites/default/files/5000100-flag%5B1%5D.jpg)
The best way to get viral material within the Scientific Community. Browse our viruses and derived products from the EVAg Portal.
A unique biological resource in the field of virology, readily available online. Users may benefit from special funding to access to products of interest, do not hesitate to apply.
An international group of 25 laboratories, including 16 EU member state institutions and 9 non-EU institutions, that represent an extensive range of virological disciplines.
An open entity aiming at developing synergies and complementary capabilities in such a way as to offer an improved access to researchers.
The quality of viruses and derived products is a key consideration when our products are to be made available. Improvements on quality process will be addressed during the project.
EVAg generates and distributes globally diagnostic materials and protocols in the event of epidemiological emergencies.
Focused on the creation of new tools, techniques and concepts to develop the infrastructure and to provide easier and less expensive access to virological materials.
A user-friendly web Portal with a continuously increasing number of viruses and derived products. Start here...
The EVAg initiative will increase competitiveness and, provides for a strong interaction with industry and a promising foundation for the innovation process between academia and industry.
- The European Commission -
The initiative has an important social impact with particular emphasis on human disease.
- The European Commission -
The quality of the installations cooperating in this consortium is excellent, representing some of the best available infrastructures across the EU and world-wide.
- The European Commission -
Finally, we hope our recommendations will be carefully considered & EVA and other biobank leaders can be further involved in the #WHO processes as a key stakeholder group
Based on EVA’s experience in pathogen sharing, during & in-between pandemics, we believe the proposed suggestions & recommendations in our Open Letter 👉 https://t.co/L06PG4WIQ5 are critical for improving pandemic prevention preparedness and response 🙌 (6/7)
3⃣ Established pathogen sharing infrastructures need to be preserved and promoted to enable efficient global pandemic prevention preparedness and response (5/7)
2⃣ #OpenAccess to pathogen sequence data should be preserved with a harmonized set of digitally-appropriate #AccessandBenefitSharing (ABS) rules that enable science to continue to thrive and be inter-operable (4/7)
1⃣ Definitions and scope of pathogen genetic resources need to be broad and flexible to enable effective pandemic prevention preparedness and response (3/7)
As negotiations progress, we strongly recommend the INB bureau and @WHO Member States to consider 3 concerns from the perspective of academic biobanks in the current WHO CA+ Zero Draft (2/7):
Transparency & stakeholder engagement are core values of the UN system 🌎We praise the efforts to develop the @WHO CA+ Zero Draft 👏However, the EVA consortium would like to raise some concerns for further consideration through our Open Letter 👉https://t.co/L06PG4WIQ5 (a 🧵 1/7)
The booth is ready (number 20-2) ! If you ever need access to a viral resource (strain, nucleic acid, protein, antibodies), or need training (microscopy, sequencing, virus isolation), you might find what you want at EVA ! #ECV2023 #H2020 https://t.co/L3H5kn4sje
Abstract ... read more
... read more
Without recording, archiving and organising information on biological material? It would be like not having Natural History Museums! Let alone what it... read more
Our lab detected first coastal Kenya COVID-19 positive cases using EVA primers. This has allowed aggressive contact tracing and case isolation. Now were are key contributors in diagnostics in the Kenya and obtaining more diagnostic kits will go a long way in supporting local and national COVID-19 response plan.
Thank you so much! The package already arrived - I am amazed. We have so much problems with the primers and probes - some did not work, some were contaminated. Your ones are the only ones which work perfectly in our hands now. With your delivery, we can go on and meanwhile try to test additional providers.
We at Luminex were sincerely appreciative of your willingness to work with us during the development of our xMAP® MultiFLEX™ Zika RNA Assay. The materials from EVAg supported our FDA submission, which is now authorized for emergency use.
Sarah M. Dunlap, PhDDirector, Clinical Operations - Luminex Corporation
We received high quality products at no cost. It helped us a lot in achieving our project. Thank you!
John UserR & D - Laboratory
